We found ourselves looking closer at the disease, the history of weight loss medications, and the potential impact of effective weight manag

This week we had Eyes On the upcoming IRA Drug pricing negotiations - here's some of the news and views we saw.

We have Eyes on Pharma Conferences this week. Don't forget to check PharmaTell Studio for the latests Planners, Insights, and Key Takes.

The MedTech sector seemed to take the brunt of the 2022 market decline but looking to forward there may be light at the end of the tunnel.

We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...

I've got Eyes On the Review / Preview Articles for the Healthcare Industry. It's interesting to see a snapshot of 2022 and some predictions

After all the quarterly results reporting, we've had eyes on product approvals, resubmissions, and a withdrawal.

This week PharmaTell had Eyes On: Heartburn – the kind caused by the upcoming Zantac litigation & resulting market jitters.

This week we had Eyes On Amazon & One Medical – as did many of you, I am sure. We saw the news and, of course, had a variety of thoughts...

We are excited to announce PharmaTech Outlook selected us as one of the Top 10 Pharma Marketing Services Companies in Europe – 2022!

The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.

As with most of you I'm sure - this week the PharmaTell Team had Eyes on ASCO + positive data for postpartum depression patients.

PharmaTell had Eyes on the US Baby Formula Shortage this week. I was curious as to how this happened

This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01

The PharmaTell Team has been busy curating Quarterly Results reports & upcoming conference planners + keeping up with Biogen next steps.

This week the team has been enjoying the spring holidays and keeping their eyes on some of the recent news from AACR and learning a bit more

This week the team has been keeping their eyes on 1Q22 Patient Volume/Procedure Updates and the Aduhelm CMS Decision.

We are excited to share the latest upgrades to PharmaTell Studio making it even easier for you to keep your eyes on you & your competition.

This week, the team has been looking at congress planners, earnings call transcripts, and the US FDA.

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.